MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

TG Therapeutics Inc

Închisă

SectorSănătate

39.82 6.21

Rezumat

Modificarea prețului

24h

Curent

Minim

36.96

Maxim

41.97

Indicatori cheie

By Trading Economics

Venit

19M

23M

Vânzări

24M

108M

P/E

Medie Sector

262.867

63.778

EPS

0.15

Marjă de profit

21.566

Angajați

338

EBITDA

17M

33M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+7.48% upside

Dividende

By Dow Jones

Următoarele câștiguri

30 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.4B

6.3B

Deschiderea anterioară

33.61

Închiderea anterioară

39.82

Sentimentul știrilor

By Acuity

61%

39%

336 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

TG Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

19 aug. 2024, 20:01 UTC

Câștiguri

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

Comparație

Modificare preț

TG Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

7.48% sus

Prognoză pe 12 luni

Medie 42.8 USD  7.48%

Maxim 55 USD

Minim 10 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruTG Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

6 ratings

5

Cumpărare

0

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

39.43 / 42.8Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

336 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.